Praluent CVOT to continue

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NYSE:SYN) said they will continue to conduct a cardiovascular outcomes trial of hypercholesterolemia drug Praluent alirocumab after an independent DMC completed a second interim analysis.

Praluent has not yet shown a CV benefit sufficient to stop the trial early. Regeneron lost $15.52 to $404.56, while Sanofi slipped EUR 0.36 to EUR 77.23 in Europe and shed $0.18 to $40.99 in New York...